Induction of energy metabolism related enzymes in yeast Saccharomyces cerevisiae exposed to ibogaine is adaptation to acute decrease in ATP energy pool.
Roman Paškulin, Polona Jamnik, Natasa Obermajer, Marija Slavić, Borut Strukelj
European Journal of Pharmacology February 10, 2010 DOI: 10.1016/j.ejphar.2009.10.032 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Saccharomyces cerevisiae yeast |
| Intervention | Ibogaine |
| Dose | 1 mg/l |
| Duration | 5 hours of exposure |
| Topics | Ibogaine |
| Keywords | Cellular metabolism Drug mechanism Yeast model |
| Citations | 13 |
| Key findings | Ibogaine induces energy metabolism enzymes in yeast as a compensatory response to decreased ATP levels, and this metabolic effect is not mediated by receptors. |
Abstract
Ibogaine has been extensively studied in the last decades in relation to its anti-addictive properties that have been repeatedly reported as being addiction interruptive and craving eliminative. In our previous study we have already demonstrated induction of energy related enzymes in rat brains treated with ibogaine at a dose of 20mg/kg i.p. 24 and 72 h prior to proteomic analysis. In this study a model organism yeast Saccharomyces cerevisiae was cultivated with ibogaine in a concentration of 1mg/l. Energy metabolism cluster enzymes glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, enolase and alcohol dehydrogenase were induced after 5h of exposure. This is a compensation of demonstrated ATP pool decrease after ibogaine. Yeast in a stationary growth phase is an accepted model for studies of housekeeping metabolism of eukaryotes, including humans. Study showed that ibogaine's influence on metabolism is neither species nor tissue specific. Effect is not mediated by binding of ibogaine to receptors, as previously described in literature since they are lacking in this model.
Comparable studies
Other experimental studies on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. In vitro (SERT) | 2007 | Laboratory study | |
| Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. | 1992 | Laboratory study | |
| The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. | 2012 | Experimental study | |
| Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. | 1995 | Experimental study | |
| Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. | 1995 | Laboratory study |
Citations in the library
Cited by 10
- The Iboga Alkaloids. Progress in the chemistry of organic natural products 2017
- Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga. Journal of Ethnopharmacology August 30, 2012
- Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes. Journal of Ethnopharmacology April 22, 2015
- Ibogaine Has Sex-Specific Plasma Bioavailability, Histopathological and Redox/Antioxidant Effects in Rat Liver and Kidneys: A Study on Females. Life December 23, 2021
- Effects of ibogaine per os application on redox homeostasis in rat liver and erythrocytes Archives of Biological Sciences December 5, 2018
and 5 more in the library
Cites 13
- Treatment of acute opioid withdrawal with ibogaine. American Journal on Addictions 1999
- The ibogaine medical subculture. Journal of Ethnopharmacology January 4, 2008
- Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption Journal of Neuroscience January 19, 2005
- Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences September 1, 2000
- GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proceedings of the National Academy of Sciences June 10, 2008
and 8 more in the library